Tetiana Taran

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

29h-index13.7kcitations59works298.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(40), Cancer Treatment and Pharmacology(16), PI3K/AKT/mTOR signaling in cancer(14), HER2/EGFR in Cancer Research(13), Cancer Genomics and Diagnostics(11)

Publications59 total

Ribociclib plus Endocrine Therapy in Early Breast Cancer
New England Journal of Medicine·2024· 298 cited
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.
Journal of Clinical Oncology·2023· 133 cited
Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Data from Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
2023Open Access
Abstract P5-02-32: Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Study
Cancer Research·2023
Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
Cancer Research·2023
Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials
Cancer Research·2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer
Therapeutic Advances in Medical Oncology·2023· 93 citedOpen Access
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.
Journal of Clinical Oncology·2022· 7 cited
Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies
Cancer Research·2022· 3 cited
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer
Cancer Research·2022· 2 cited
Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer
Cancer Research·2022· 11 cited
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
JCO Precision Oncology·2021· 39 citedOpen Access
Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
Journal of Clinical Oncology·2021· 41 cited
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Journal of Clinical Oncology·2021· 140 citedOpen Access
Abstract GS1-04: Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies
Cancer Research·2021· 4 cited
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.
Journal of Clinical Oncology·2020· 65 cited
Abstract PD2-08: Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study
Cancer Research·2020· 11 cited
page 1 of 3Next →

Frequent Co-authors

Gabriel N. Hortobágyi(17), Howard A. Burris(17), Sara A. Hurvitz(15), Mario Campone(14), Fabrice André(14), Seock‐Ah Im(12), José Baselga(11), Dennis J. Slamon(11), Shinzaburo Noguchi(11), Guy Jérusalem(10), Aditya Bardia(10), Martine Piccart(10), Hope S. Rugo(10), Kathleen I. Pritchard(9), Tarek Sahmoud(9), Patrick Neven(8), Arunava Chakravartty(8), Katarína Petráková(7), Yen‐Shen Lu(7), Karen Rodriguez-Lorenc(7)